LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

NCT02649673 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

34

Enrollment

OTHER

Sponsor class

Stopped Clinical program was discontinued by Novartis

Conditions

Small Cell Lung Cancer
Ovarian Cancer

Interventions

DRUG: LCL161
DRUG: Topotecan
DRUG: Pegylated GCSF (PEG-GCSF)

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]